Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
What’s Your Call?
Collective community sentiment on Infinium Pharmachem Ltd
Your Vote -
Buy
66.67%
Hold
16.67%
Sell
16.67%
66.67%
6 users have voted
Market Depth
How many stocks are available to buy or sell and at what prices.
Buy Order Quantity
0%
Sell Order Quantity
100%
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Bid Price
Qty
299.00
500
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
500
Option Chain
Analyzes market sentiment, predicts Infinium Pharmachem Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Infinium Pharmachem - Price movement
-
Infinium Pharmachem has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025
-
Infinium Pharmachem - Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter
-
Infinium Pharmachem - Certificate under SEBI (Depositories and Participants) Regulations, 2018
-
Infinium Pharmachem - Trading Window
-
Infinium Pharmachem - Trading Window-XBRL
-
Infinium Pharmachem - Statement of deviation(s) or variation(s) under Reg. 32
Key fundamentals
Evaluate the intrinsic value of Infinium Pharmachem Ltd stock
Name | March-24 | March-23 | March-22 | March-21 | |
---|---|---|---|---|---|
Assets | 63.1086 | 21.6989 | 12.5498 | 7.0463 | |
Liabilities | 63.1086 | 21.6989 | 12.5498 | 7.0463 | |
Equity | 13.9161 | 5.083 | 1.0166 | 1.0166 | |
Gross Profit | 17.4175 | 15.207 | 8.7192 | 4.9109 | |
Net Profit | 11.0933 | 9.1491 | 5.5034 | 2.7194 | |
Cash From Operating Activities | -15.0336 | 7.3494 | 9.1365 | 6.816 | |
NPM(%) | 9.06 | 9.03 | 7.43 | 4.98 | |
Revenue | 122.3577 | 101.3062 | 74.0377 | 54.5579 | |
Expenses | 104.9401 | 86.0991 | 65.3185 | 49.647 | |
ROE(%) | 17.55 | 14.47 | 8.7 | 4.3 |
Corporate Action
XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
---|
Peers
Other companies within the same industry or sector that are comparable to Infinium Pharmachem Ltd
Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
---|---|---|---|---|---|---|
Albert David Ltd | 840.85 | 0.23 | 11.87 | 0.00 | 1321.50 | 1.37 |
Lotus Eye Hospital and Institute Ltd | 81.36 | 2.94 | 339.00 | 0.00 | 14.01 | 0.61 |
Vaishali Pharma Ltd | 13.72 | -0.15 | 457.33 | 0.00 | 2.76 | 0.00 |
Astec Lifesciences Ltd | 693.05 | -1.61 | 0.00 | 0.00 | -687.11 | 0.00 |
Company Info
The Company was originally incorporated as Private Limited, under the Companies Act, 1956 ("Companies Act") in the name and style of "M/s Infinium Pharmachem Private Limited" on November 21st, 2003 under the provisions of the Companies Act, 1956 vide Certificate of Incorporation issued by the Registrar of Companies, Ahmedabad, Gujarat. Later on, company was converted into public limiteds company, the name of the Company was changed to "Infinium Pharmachem Limited" and fresh Certificate of Incorporation dated August 12th, 2022 was issued by the Registrar of Companies, Ahmedabad, Gujarat. Infinium Pharmachem Limited, well focused to Iodine chemistry & this is the only core area of ours. We are working as CRAMS, but the domain is very restricted to Iodine chemistry & it revolves around Iodine derivatives or Iodination. The company also providing fully integrated customized services from R & D to Commercial scale manufacturing and packaging for our products to the Pharmaceutical, Agrochemical,Nutraceutical, Speciality Chemicals & various other chemical Industries.The supply range of Iodine derivatives on Order to Made basis only. However, we keep in ready stock many of well demanded products. MAJOR EVENTS : 2003 - Established with a vision to be a globally integrated and admired Pharmaceutical and Healthcare Company. 2004 -Started iodine derivatives manufacturing plant at Gujarat, India. 2010 -Set up R & D Unit and Certified as ISO 90001-2008. 2011 - Penetrated the Pharmaceutical market with the CRAMS model. 2014 - Upgraded Plant with GMP compliant large scale manufacturing facility. 2015 -Obtained FDA approval for manufacturing of APIs. 2017 -Certified as WHO-GMP and ISO 14001-2015. 2018 -Product Portfolio touched 200 Iodine Derivatives and 7 APIs. 2019 -Expanded reach to over 15 countries across the globe. 2021 -Augmentation of production capacity and construction of new Premises. 2022 - Incorporated subsidiary company in bio-fuel segment for backwar 2023 -The Company has issued Bonus Shares in the Ratio of 1:1. - 'Commencement Of Production By Subsidiary Company'. 2024 -Infinium Pharmachem Ltd CommencesConstruction of New Project for manufacturing Contrast Media Raw Materials. -Infinium Pharmachem Limited has informed the Exchange about Acquisition of equity shares of Infinium Healthcare Private Limited.
The Company was originally incorporated as Private Limited, under the Companies Act, 1956 ("Companies Act") in the name and style of "M/s Infinium Pharmachem Private Limited" on November 21st, 2003 under the provisions of the Companies Act, 1956 vide Certificate of Incorporation issued by the Registrar of Companies, Ahmedabad, Gujarat. Later on, company was converted into public limiteds company, the name of the Company was changed to "Infinium Pharmachem Limited" and fresh Certificate of Incorporation dated August 12th, 2022 was issued by the Registrar of Companies, Ahmedabad, Gujarat. Infinium Pharmachem Limited, well focused to Iodine chemistry & this is the only core area of ours. We are working as CRAMS, but the domain is very restricted to Iodine chemistry & it revolves around Iodine derivatives or Iodination. The company also providing fully integrated customized services from R & D to Commercial scale manufacturing and packaging for our products to the Pharmaceutical, Agrochemical,Nutraceutical, Speciality Chemicals & various other chemical Industries.The supply range of Iodine derivatives on Order to Made basis only. However, we keep in ready stock many of well demanded products. MAJOR EVENTS : 2003 - Established with a vision to be a globally integrated and admired Pharmaceutical and Healthcare Company. 2004 -Started iodine derivatives manufacturing plant at Gujarat, India. 2010 -Set up R & D Unit and Certified as ISO 90001-2008. 2011 - Penetrated the Pharmaceutical market with the CRAMS model. 2014 - Upgraded Plant with GMP compliant large scale manufacturing facility. 2015 -Obtained FDA approval for manufacturing of APIs. 2017 -Certified as WHO-GMP and ISO 14001-2015. 2018 -Product Portfolio touched 200 Iodine Derivatives and 7 APIs. 2019 -Expanded reach to over 15 countries across the globe. 2021 -Augmentation of production capacity and construction of new Premises. 2022 - Incorporated subsidiary company in bio-fuel segment for backwar 2023 -The Company has issued Bonus Shares in the Ratio of 1:1. - 'Commencement Of Production By Subsidiary Company'. 2024 -Infinium Pharmachem Ltd CommencesConstruction of New Project for manufacturing Contrast Media Raw Materials. -Infinium Pharmachem Limited has informed the Exchange about Acquisition of equity shares of Infinium Healthcare Private Limited.
Read More
Parent Organisation
Infinium Pharmachem Ltd.
Founded
21/11/2003
Managing Director
Mr.Sanjaykumar Viththalbhai Patel
NSE Symbol
INFINIUMSM
FAQ
The current price of Infinium Pharmachem Ltd is
The 52-week high for Infinium Pharmachem Ltd is
The market capitalization of Infinium Pharmachem Ltd is currently
This value can fluctuate based on stock price movements and changes in the number of shares outstanding.To buy Infinium Pharmachem Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Infinium Pharmachem Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Infinium Pharmachem Ltd shares.
The CEO of Infinium Pharmachem Ltd is Mr.Sanjaykumar Viththalbhai Patel, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.